Ipamorelin — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Delayed gastric emptying and gastrointestinal motility effects
Anchor outcome. Gastric emptying half-time by scintigraphy or breath test.
Effect as recorded. A phase 2 programme in post-operative ileus did not meet its primary endpoint and development was discontinued; negative result.[1,2]
Certainty. Moderate certainty The Institute regards the existence of a discontinued phase 2 programme with a negative primary endpoint as the most clinically informative fact about this compound, and notes that it is almost never mentioned in supply-side material.
Contributing trials. IPA-PH2-POI. Full structured abstracts are published for each.
Full evidence extract for delayed gastric emptying and gastrointestinal motility effects · Indication assessment
§3.2Growth hormone deficiency and growth-hormone secretagogue pharmacology
Anchor outcome. Peak stimulated growth hormone.
Effect as recorded. Dose-dependent growth-hormone release demonstrated in preclinical models and in early human study; pharmacodynamic; no confirmatory human efficacy estimate.[2,3]
Certainty. Low certainty The preclinical pharmacology is well characterised. Human data are limited to early-phase work.
Contributing trials. IPA-PH1-GH · IPA-PH2-POI. Full structured abstracts are published for each.
Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment
§3.3Sarcopenia and lean-mass preservation during weight reduction
Anchor outcome. Change in appendicular lean mass by DXA.
Effect as recorded. No randomised human evidence identified; —.[3,4]
Certainty. Very low certainty Body-composition claims are not supported by trial evidence.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for sarcopenia and lean-mass preservation during weight reduction · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998;139(5):552–561. doi:10.1530/eje.0.1390552 · PMID 9849822
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805. doi:10.1210/jc.2005-1536 · PMID 16352683
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.